Sialic Acid Binding Ig-like Lectin 2
"Sialic Acid Binding Ig-like Lectin 2" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A lectin and cell adhesion molecule found in B-LYMPHOCYTES. It interacts with SIALIC ACIDS and mediates signaling from B-CELL ANTIGEN RECEPTORS.
| Descriptor ID |
D051918
|
| MeSH Number(s) |
D12.776.395.550.200.810 D12.776.503.921.200 D12.776.543.550.200.810 D23.050.301.350.720
|
| Concept/Terms |
Sialic Acid Binding Ig-like Lectin 2- Sialic Acid Binding Ig-like Lectin 2
- Sialic Acid Binding Ig like Lectin 2
- CD22 Glycoprotein
- Glycoprotein, CD22
- Siglec-2
- Antigens, CD22
- CD22 Antigens
- B-Lymphocyte Cell Adhesion Molecule
- B Lymphocyte Cell Adhesion Molecule
- CD22 Antigen
- Antigen, CD22
|
Below are MeSH descriptors whose meaning is more general than "Sialic Acid Binding Ig-like Lectin 2".
Below are MeSH descriptors whose meaning is more specific than "Sialic Acid Binding Ig-like Lectin 2".
This graph shows the total number of publications written about "Sialic Acid Binding Ig-like Lectin 2" by people in this website by year, and whether "Sialic Acid Binding Ig-like Lectin 2" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2013 | 0 | 2 | 2 |
| 2014 | 0 | 1 | 1 |
| 2016 | 1 | 0 | 1 |
| 2019 | 0 | 1 | 1 |
| 2021 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Sialic Acid Binding Ig-like Lectin 2" by people in Profiles.
-
Inotuzumab Ozogamicin for Relapsed/Refractory Acute Lymphoblastic Leukemia in the INO-VATE Trial: CD22 Pharmacodynamics, Efficacy, and Safety by Baseline CD22. Clin Cancer Res. 2021 05 15; 27(10):2742-2754.
-
Inotuzumab: from preclinical development to success in B-cell acute lymphoblastic leukemia. Blood Adv. 2019 01 08; 3(1):96-104.
-
Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia. N Engl J Med. 2016 Aug 25; 375(8):740-53.
-
SWOG S0910: a phase 2 trial of clofarabine/cytarabine/epratuzumab for relapsed/refractory acute lymphocytic leukaemia. Br J Haematol. 2014 May; 165(4):504-9.
-
B-cell transcription factor expression and immunoglobulin gene rearrangement frequency in acute myeloid leukemia with t(8;21)(q22;q22). Am J Clin Pathol. 2013 Sep; 140(3):355-62.
-
Nuclear protein dysregulation in lymphoplasmacytic lymphoma/waldenstrom macroglobulinemia. Am J Clin Pathol. 2013 Feb; 139(2):210-9.